Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2010 (2010), Article ID 612619, 7 pages
http://dx.doi.org/10.4061/2010/612619
Review Article

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease

1Boehringer Ingelheim Pharma GmbH & Co. KG, Pharmaceutical Development, 88397 Biberach, Germany
2Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Research, 88397 Biberach, Germany
3Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Metabolism and Pharmacokinetics, 88397 Biberach, Germany
4Department of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, Germany

Received 16 September 2010; Accepted 10 November 2010

Academic Editor: Katherine Grosset

Copyright © 2010 Wolfram Eisenreich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. A. Grosset, I. Bone, and D. G. Grosset, “Suboptimal medication adherence in Parkinson's disease,” Movement Disorders, vol. 20, no. 11, pp. 1502–1507, 2005. View at Publisher · View at Google Scholar · View at PubMed
  2. M. Dziedzicka-Wasylewska, F. Ferrari, R. D. Johnson et al., “Mechanisms of action of pramipexole: effects on receptors,” Reviews in Contemporary Pharmacotherapy, vol. 12, no. 1-2, pp. 1–31, 2001. View at Google Scholar
  3. T. Kvernmo, S. Härtter, and E. Burger, “A review of the receptor-binding and pharmacokinetic properties of dopamine agonists,” Clinical Therapeutics, vol. 28, no. 8, pp. 1065–1078, 2006. View at Publisher · View at Google Scholar · View at PubMed
  4. J. Mierau, F. J. Schneider, H. A. Ensinger, C. L. Chio, M. E. Lajiness, and R. M. Huff, “Pramipexole binding and activation of cloned and expressed dopamine D, D and D receptors,” European Journal of Pharmacology, vol. 290, no. 1, pp. 29–36, 1995. View at Google Scholar
  5. T. Friedl, S. Härtter, and W. J. Eisenreich, “Development of a once daily formulation for Pramipexole,” in Proceedings of the 6th German-Scandinavian Meeting on Movement Disorders, Gothenburg, Sweden, 2009, Poster.
  6. P. Jenner, M. Könen-Bergmann, C. Schepers, and S. Haertter, “Pharmacokinetics of a Once-Daily extended-release formulation of pramipexole in healthy male volunteers: three studies,” Clinical Therapeutics, vol. 31, no. 11, pp. 2698–2711, 2009. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Koenen-Bergmann, S. Haertter, and C. Schepers, “A multiple rising-dose bioequivalence phase I study with a pramipexole extended release (ER) formulation,” in Proceedings of the 12th Congress of the European Federation of Neurological Societie, Madrid, Spain, 2008, Poster (P1248).
  8. European Medicines Agency, “Pramipexole (Mirapexin® prolonged-release tablets): summary of product characteristics,” February 2010, http//www.emea.europa.eu/humandocs/PDFs/EPAR/Sifrol/emea-combined-h133en.pdf.
  9. C. Dansirikul, A. Staab, L. Salin, S. Haertter, and T. Lehr, “Population pharmacokinetic analysis of pramipexole extended-release formulation in Parkinson's disease (PD) patients,” in Proceedings of the 18th Annual Meeting of the Population Approach Group in Europe (PAGE '09), St. Petersburg, Russia, 2009, Poster (P09-085465).
  10. C. M. Chwieduk and M. P. Curran, “Pramipexole extended release: in parkinsons disease,” CNS Drugs, vol. 24, no. 4, pp. 327–336, 2010. View at Publisher · View at Google Scholar · View at PubMed
  11. J. C. Möller and W. H. Oertel, “Pramipexole in the treatment of Parkinson's disease: new developments,” Expert Review of Neurotherapeutics, vol. 5, no. 5, pp. 581–586, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. O. Rascol, P. Barone, C. D. Debieuvre et al., “Overnight switching from immediate- to extended-release (ER) in early Parkinson's disease,” Neurology, vol. 72, no. 11, supplement, p. A320, 2009. View at Google Scholar
  13. Y. Mizuno, M. Yamamoto, S. Kuno, K. Hasegawa, N. Hattori, and T. Kagimura, “Efficacy of pramipexole extended release (ER) and switching from pramipexole immediate release (IR) to ER in Japanese advanced Parkinson’s disease (PD) patients,” in Proceedings of the 18th WFN World Congress on Parkinson’s Disease and Related Disorders, Miami Beach, Fla, USA, 2009, Poster 2.192.
  14. W. Poewe, P. Barone, R. A. Hauser et al., “Pramipexole extended-release is effective in early Parkinson's disease,” Movement Disorders, vol. 24, supplement 1, p. S273, 2009. View at Google Scholar
  15. L. Salin, R. Hauser, and J. Koester , “Double-blind evaluation of maintenance of efficacy of pramipexole extended-release in early Parkinson's disease,” in Proceedings of the 61st Annual Meeting of the American Academy of Neurology, Seattle, Wash, USA, 2009, abstract P06.150, Neurology 72:11.
  16. R. Hauser, L. Salin, and J. Koester, “Double-blind evaluation of pramipexole extended-release (ER) in early Parkinson's disease,” Neurology, vol. 72, no. 11, supplement 3, pp. A412–A413, 2009. View at Google Scholar
  17. A. Schapira, P. Barone, R. A. Hauser et al., “Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease,” in Proceedings of the 13th Annual International Congress of Parkinson's Disease and Movement Disorders, 2009, Poster WE-199.
  18. W. H. Jost, “Gastrointestinal dysfunction in Parkinson's Disease,” Journal of the Neurological Sciences, vol. 289, no. 1-2, pp. 69–73, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus